TransMedics Group, Inc.
Rank #282HypergrowthTMDX · Nasdaq · Healthcare
TransMedics Group, Inc. (TMDX) — Rank #282 by gross profitability (GP/assets 0.25) · ROE 36.7% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001756262 · all metrics point-in-time as of the filing date.
About
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Show moreShow less
The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- transmedics.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-27 | 2022-12-31filed 2023-02-27 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 27.2 | 19.8 | 8.2 | 3.5 |
| Stock-based compensation | 36.9 | 33.2 | 19.8 | 10.3 |
| Change in receivables | (14.0) | 34.3 | 33.8 | 21.7 |
| Change in inventory | 7.7 | 8.4 | 28.1 | 8.0 |
| Change in payables | (0.0) | (1.4) | 7.0 | (3.3) |
| Operating cash flow | 192.8 | 48.8 | (13.0) | (45.8) |
| Investing | ||||
| Capital expenditures | 59.3 | 129.7 | 151.8 | 11.9 |
| Investing cash flow | (59.3) | (129.3) | (194.0) | 54.5 |
| Financing | ||||
| Debt issued | — | — | — | 58.5 |
| Debt repaid | — | — | — | 36.1 |
| Financing cash flow | 16.9 | 22.9 | 400.4 | 167.9 |
| Summary | ||||
| Free cash flow | 133.6 | (80.9) | (164.9) | (57.7) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?